Physician News – Aspen Pharmacare Australia

IMPORTANT NOTIFICATION: Zantac (Ranitidine) Recall

October 2, 2019

Dear Doctor, Aspen Pharmacare Australia Pty Ltd, in consultation with the Therapeutic Goods Administration (TGA), is conducting a retail level recall of Zantac (ranitidine) tablets, effervescent tablets, syrup and ampoules. The TGA has not requested that a Dear Doctor letter be sent for this retail level product recall. We are informing you as the potentially…

ANNOUNCEMENT – Aspen Pharmacare – Potential Contamination of Ranitidine with NDMA

September 20, 2019

On Thursday evening 19th September 2019 the TGA announced the requirement for all sponsors of ranitidine to suspend supply, and initiate a product hold, at their warehouses. Therefore as of Friday 20th September 2019 Aspen has suspended the supply of all Zantac® products to pharmacy wholesalers and to all retailers. Download Letter

ANNOUNCEMENT – Aspen Pharma – QUARANTINE STATUS LIFTED and PRODUCT DEFECT CORRECTION – ENDONE oxycodone hydrochloride 5mg tablet pack

July 31, 2019

It has been incorrectly reported in the media that Endone 5mg tablets are the subject of a product recall. Aspen Pharma wishes to advise that there is currently NO RECALL of this medicine. The quarantine placed on the product from the above batch has been lifted, Endone is available for prescribing and dispensing. Download Letter…

ANNOUNCEMENT – Aspen Pharmacare – Stock status notification for ZYBANSR(Bupropion hydrochloride)150 mg tablets

July 17, 2019

Aspen Pharmacare Australia wish to notify you that we are experiencing an ongoing supply disruption which has resulted in a long term out of stock status for ZYBANSR(Bupropion hydrochloride)150 mg tablets.

ANNOUNCEMENT – Aspen Pharmacare – LIVIAL® (tibolone) returning to MSD

May 30, 2018

Aspen wishes to advise you that responsibility for LIVIAL® (tibolone) will be returning to MSD, who are the Sponsor of this product, effective 1 June 2018.

ANNOUNCEMENT – Aspen Pharmacare – Notification of some Marcain, Xylocaine and Naropin Product Shortage

April 30, 2018

Following on from the notification Aspen sent (dated 29th March 2018) regarding Marcain, Xylocaine and Naropin product shortages due to a fire at AstraZeneca’s (AZ) Swedish manufacturing site, Aspen would like to provide you with the following update:

ANNOUNCEMENT – Aspen Pharmacare – DISCONTINUATION OF DI-GESIC

March 9, 2018

Aspen Pharmacare wish to advise that Di-Gesic will be discontinued effective 1 April 2018. Regrettably, Aspen has been unable to procure suitable Active Pharmaceutical Ingredient to continue manufacture and supply of Di-Gesic in Australia. The Therapeutic Goods Administration has been notified and the product has been placed on the “Medicine Shortages Information” list. Please see the attached letter for further information.

ANNOUNCEMENT – Aspen Pharmacare – Notification of some Marcain®, Xylocaine® and Naropin® Product Shortage

December 7, 2017

Aspen is currently experiencing stock shortages for a range of local anaesthetic products. We are currently working in collaboration with our supplier, AstraZeneca (AZ) to expedite the re-establishment of adequate supply to all markets.

ANNOUNCEMENT – Aspen Pharmacare – DISCONTINUATION OF DI-GESIC(dextropropoxyphene Hcl 32.5 mg. paracetamol 325 mg)

November 22, 2017

Aspen Pharmacare advises that Di-Gesic will be discontinued effective 1 April 2018.

ANNOUNCEMENT – Aspen Pharmacare – ASPEN FENTANYL (fentanyl citrate) injection is back in stock

August 23, 2017

Aspen is pleased to advise that both presentations of ASPEN Fentanyl injection are back in stock in Australia and are available to order from your wholesaler.

Links to some of our other websites: